Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain StimulationGALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024.Key HighlightsRevenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as repo ...